ShuYu Civilian Pharmacy Corp Ltd

The company’s capital structure is characterized by a debt-to-equity ratio of 1.6, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.9, suggesting limited short-term liquidity cushion. The price-to-book ratio of 2.55 and price-to-tangible-book ratio of 2.55 imply that the market values the company at a premium to its book value, but this is partially offset by a high debt load. Profitability metrics show a return on equity (ROE) of 5.36% and a return on assets (ROA) of 1.21%, both below the typical thresholds for high-margin retail operations. The gross profit margin is 26.05% (2,691 million CNY gross profit on 10,327 million CNY revenue), but operating income of 186.5 million CNY and net income of 114.2 million CNY suggest significant operating expenses and a thin operating margin of 1.80%. These figures are below the median for the Drug Retailers industry, which typically sees higher ROE and ROA due to tighter cost controls and higher volume leverage. Geographically, the company is heavily concentrated in Shandong Province, with no disclosed revenue diversification beyond this region. Segment-wise, the business is entirely retail-focused, with no manufacturing or wholesale operations reported. This concentration increases exposure to regional economic shifts and regulatory changes in Shandong, which could impact customer demand and supply chain stability. The company’s growth trajectory is modest, with no disclosed revenue growth rates in the latest period. Outlook data indicates a projected revenue increase of 3.2% in the current fiscal year and 2.8% in the next, driven by incremental store openings and product diversification. However, these growth rates are below the industry median of 5.5% and suggest limited scalability in the current market structure. Risk factors include a medium liquidity risk due to the current ratio of 0.9 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no recent share issuance or ATM/shelf registration activity reported. However, the company’s high debt load and low free cash flow (261.1 million CNY) could limit its ability to fund expansion without external financing, potentially increasing dilution risk in the future. Recent events include a 10-K filing disclosing the company’s reliance on a single regional market and a transcript from a recent earnings call highlighting plans to expand into adjacent health product categories. No major regulatory or legal issues were disclosed in the latest filings.